Please assess the completion status of the following clinical trial:

Trial Title: A Study of Avastin (Bevacizumab) Plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, \>=18 years of age~* Metastatic colorectal cancer and disease progression~* Previously treated with first-line chemotherapy plus Avastin~* Eastern Cooperative Oncology Group (ECOG) performance status \<=2.~Exclusion Criteria:~* Diagnosis of progression of disease more than 3 months after last Avastin administration~* First-line patients with progression-free survival in first-line of \<3 months~* Patients receiving less than 3 consecutive months of Avastin in first-line therapy~* Past or current history (within the last 2 years prior to treatment start) of other malignancies, except for curatively treated basal and squamous cell cancer of the skin or in situ cancer of the cervix~* Clinically significant cardiovascular disease within 6 months prior to start of study treatment~* Known central nervous system (CNS) disease, except for treated CNS metastases as defined by protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chemotherapy (Type: ACTIVE_COMPARATOR): Chemotherapy alone until disease progression, unacceptable toxicity, or patient refusal
- Chemotherapy + Bevacizumab (Type: EXPERIMENTAL): Chemotherapy and Bevacizumab until disease progression, unacceptable toxicity, or patient refusal

Based on this trial design, predict the completion outcome and termination type (if applicable).